Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $44.2857.

A number of equities analysts recently commented on ZBIO shares. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings lowered shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Morgan Stanley lifted their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th.

Zenas BioPharma Stock Down 1.6%

NASDAQ:ZBIO opened at $32.29 on Wednesday. The stock’s fifty day moving average is $23.58 and its two-hundred day moving average is $22.35. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. Zenas BioPharma has a 52 week low of $13.50 and a 52 week high of $44.60. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -3.81 and a beta of -0.96.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter in the previous year, the company earned ($0.80) EPS. Research analysts anticipate that Zenas BioPharma will post -4.47 EPS for the current year.

Insider Activity at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. bought 60,000 shares of Zenas BioPharma stock in a transaction dated Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the acquisition, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP increased its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma during the third quarter worth $30,000. GF Fund Management CO. LTD. purchased a new position in Zenas BioPharma in the fourth quarter worth $38,000. BNP Paribas Financial Markets increased its holdings in shares of Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares in the last quarter. Finally, CWM LLC boosted its stake in shares of Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after acquiring an additional 709 shares in the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.